Literature DB >> 11533818

Frequency of herpes simplex virus in Syria based on type-specific serological assay.

A I Ibrahim1, K M Kouwatli, M T Obeid.   

Abstract

OBJECTIVE: This study aimed to determine the seroprevalence of herpes simplex virus types 1 and 2 antibodies in Syrian populations. Serum samples collected between 1995-1998 from a total of 1293 healthy persons, neonates, pregnant women, labial herpes patients, kidney transplantation patients, atherosclerosis patients, cervical cancer patients, patients with suspected herpetic keratitis, viral encephalitis patients, patients with sexually transmitted diseases, AIDS patients, female prostitutes and bar girls.
METHODS: Serum samples were studied by enzyme immunosorbent assay using herpes simplex virus type-specific antigen, glycoprotein (gG).
RESULTS: In the healthy group, herpes simplex virus type 1 infections correlated mostly with age and was prevalent among subjects >30 years (approximately 95% of persons in our country have herpes simplex virus type 1 antibodies by 30 years of age), while they varied moderately among other groups. Herpes simplex virus type 2 prevalence varied greatly among the groups defined by sexual activity and was associated with risk behavior for prostitution. Herpes simplex virus type 2 seroprevalence was highest among prostitutes (34%) and bar girls (20%); lowest in healthy persons (0.15%); and intermediate in sexually transmitted disease patients (9.5%), cervical cancer patients (8%) and AIDS patients (4%).
CONCLUSION: It can be concluded that infection of herpes simplex virus type 2 is very rare in persons in our country.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11533818

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  6 in total

Review 1.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

2.  Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.

Authors:  Sarah Samandary; Hédia Kridane-Miledi; Jacqueline S Sandoval; Zareen Choudhury; Francina Langa-Vives; Doran Spencer; Aziz A Chentoufi; François A Lemonnier; Lbachir BenMohamed
Journal:  Hum Immunol       Date:  2014-05-04       Impact factor: 2.850

3.  Prevalence of herpes simplex virus (types 1 and 2), varicella-zoster virus, cytomegalovirus, and human herpesvirus 6 and 7 DNA in cerebrospinal fluid of Middle Eastern patients with encephalitis.

Authors:  Ali I Ibrahim; Michel T Obeid; Muhidien J Jouma; Klaus Roemer; Nikolaus Mueller-Lantzsch; Barbara C Gärtner
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  Estimating seroprevalence of herpes simplex virus type 1 among different Middle East and North African male populations residing in Qatar.

Authors:  Gheyath K Nasrallah; Soha R Dargham; Layla I Mohammed; Laith J Abu-Raddad
Journal:  J Med Virol       Date:  2017-09-12       Impact factor: 2.327

5.  Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions.

Authors:  Sonia Chaabane; Manale Harfouche; Hiam Chemaitelly; Guido Schwarzer; Laith J Abu-Raddad
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

6.  Epidemiology of Treponema pallidum, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and herpes simplex virus type 2 among female sex workers in the Middle East and North Africa: systematic review and meta-analytics.

Authors:  Hiam Chemaitelly; Helen A Weiss; Alex Smolak; Elzahraa Majed; Laith J Abu-Raddad
Journal:  J Glob Health       Date:  2019-12       Impact factor: 4.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.